NORTHVALE, N.J., Nov. 9, 2007 (PRIME NEWSWIRE) -- Elite Pharmaceuticals, Inc. (AMEX:ELI - News) (the ``Company’’) today announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on a Phase 3 trial of ELI-216, Elite’s Abuse Deterrent Oxycodone product. Elite is now cleared to commence the Phase 3 clinical trials.
